

25-119, 25-118, 25-117, 25-116, 25-115, 26-122, 26-121, 26-120, 26-119, 26-118, 26-117, 26-116, 26-115, 27-122, 27-121, 27-120, 27-119, 27-118, 27-117, 27-116, 27-115, 28-122, 28-121, 28-120, 28-119, 28-118, 28-117, 28-116, 28-115, 29-122, 29-121, 29-120, 29-119, 29-118, 29-117, 29-116, 29-115, 30-122, 30-121, 30-120, 30-119, 30-118, 30-117, 30-116, 30-115, 31-122, 31-121, 31-120, 31-119, 31-118, 31-117, 31-116, 31-115, 32-122, 32-121, 32-120, 32-119, 32-118, 32-117, 32-116, or 32-115 of SEQ ID NO: 16;

or variants and derivatives thereof; provided however, that when the truncated sTNFR polypeptide comprises the amino acid residues 15-122, 16-122, 17-122, 18-122, 19-122, 20-122, 21-122, 22-122, 23-122, 24-122, 25-122, 26-122, 27-122, 28-122, 29-122, 30-122, 31-122, or 32-122 of SEQ ID NO: 16, the polypeptide does not further comprise amino acid residues 123-179 of SEQ ID NO: 16, or a portion thereof; and optionally further comprising an amino-terminal methionine.

### REMARKS

**Claim Status.** Claims 1 to 31 are pending in the application. Claims 1 and 3 are amended hereby. No claim has been added or canceled.

**Support for Amendments.** In order to bring the instant application into compliance with 37 C.F.R. § 1.822(e), Applicants amended the specification and claims in a Preliminary Amendment filed January 29, 2002. Applicants noticed in preparing the instant response that the amendments of January 29, 2002 resulted in the inadvertent omission of certain contiguous fragments, particularly those extending only to residue 103 at the C-terminus and those beginning at residue 19 at the N-terminus. Such fragments are clearly supported in the specification prior to the amendment of January 29, 2002 (*see, e.g.,* page 6, line 8 *et seq.*). Applicants seek entry of the above-described amendments solely to correct these inadvertent omissions and contend that no new matter has been added by these amendments.

**Election under Restriction Requirement.** Applicants elect to prosecute claims 1-12, 22-25, 28, and 31, designated as Group A by the Examiner. The Action states that the claims of Group A are drawn to truncated sTNFR polypeptides. Applicants further elect to prosecute the claims that are drawn to the sTNFR polypeptide of SEQ ID NO: 2, with traverse. Applicants also elect the species of truncated sTNFR polypeptide comprising amino acid residues 1-105 of SEQ ID NO: 2, further comprising an amino-terminal methionine (*i.e.,* the species of truncated



sTNFR polypeptide comprising the amino acid sequence of SEQ ID NO: 8). The Action states that the specific truncations of the polypeptide of SEQ ID NO: 2 that are listed in claim 1 constitute patentably distinct species of the claimed invention. The basis for Applicants' traversal of the requirement is as follows.

Applicants respectfully submit that there will be no undue hardship on the Office in performing a search with respect to the sTNFR-I polypeptides of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14. The truncated sTNFR-I polypeptides of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14 share 100% sequence identity with residues 19-104 of the sTNFR-I polypeptide of SEQ ID NO: 2 (see Exhibit A, which contains a sequence alignment performed using the application MacVector 7.1.1 (Accelrys, Cambridge, UK; <http://www.accelrys.com>) at the default settings). The relationship of the truncated sTNFR-I polypeptides of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14 to the sTNFR-I polypeptide of SEQ ID NO: 2 is shown in Table I.

Table I

SEQ ID NO:	Construct	Relationship to SEQ ID NO: 2
4	sTNFR-I 2.6D/C105	residues 1-105 of SEQ ID NO: 2, further comprising an amino-terminal methionine, and having a Cys substitution at position 105
6	sTNFR-I 2.6D/C106	residues 1-108 of SEQ ID NO: 2, further comprising an amino-terminal methionine
8	sTNFR-I 2.6D/N105	residues 1-105 of SEQ ID NO: 2, further comprising an amino-terminal methionine
10	sTNFR-I 2.3D/d8	residues 19-105 of SEQ ID NO: 2, further comprising an amino-terminal methionine
12	sTNFR-I 2.3D/d18	residues 9-105 of SEQ ID NO: 2, further comprising an amino-terminal methionine
14	sTNFR-I 2.3D/d15	residues 16-105 of SEQ ID NO: 2, further comprising an amino-terminal methionine, and having a Ser substitution at position 18

As indicated in Table I, the truncated sTNFR-I polypeptides of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14 comprise species



of the genus of truncated sTNFR polypeptides of claim 1 (i.e., the polypeptides of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, and SEQ ID NO: 12 are fragments of SEQ ID NO: 2, and the polypeptides of SEQ ID NO: 4 and SEQ ID NO: 14 are fragments of SEQ ID NO: 2 having a single amino acid substitution). As the polypeptides of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, and SEQ ID NO: 14 comprise species of the specific truncations of the polypeptide of SEQ ID NO: 2 that are listed in claim 1, Applicants respectfully request reconsideration of the restriction requirement of section 3 of the instant Action.

Applicants enclose a petition for a one-month extension of time. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.

**Conclusion.** If Examiner O'Hara believes it to be helpful, she is invited to contact the undersigned representative by telephone at (312) 913-0001. In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments, removal of all requirements, and allowance of all claims.

Respectfully submitted,  
**McDonnell Bochen Hulbert & Berghoff**

Dated: November 12, 2002

By:


  
Donald L. Zuhn, Ph.D.  
Reg. No. 48,710



EXHIBIT A

ClustalW (v1.4) multiple sequence alignment

7 Sequences Aligned  
Gaps Inserted = 0Alignment Score = 14527  
Conserved Identities = 86

```

SEQ02      1  DSVCPQGKYIHPQNNsicCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  49
SEQ04      1  MDSVCPQGKYIHPQNNsicCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  50
SEQ06      1  MDSVCPQGKYIHPQNNsicCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  50
SEQ08      1  MDSVCPQGKYIHPQNNsicCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  50
SEQ10      1               MCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  32
SEQ12      1             MYIHPQNNsicCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  42
SEQ14      1             MSISCTKCHKGTYLYNDCPGPGQDTDCRECESGSF  35
                *****

```

```

SEQ02      50  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN  99
SEQ04      51  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN 100
SEQ06      51  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN 100
SEQ08      51  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN 100
SEQ10      33  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN  82
SEQ12      43  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN  92
SEQ14      36  TASENHLRHCLSCSKCRKEMGQVEISSCTVDRDTCVCGCRKNQYRHYWSEN  85
                *****

```

```

SEQ02     100  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL 149
SEQ04     101  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL 106
SEQ06     101  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL 109
SEQ08     101  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL 106
SEQ10      83  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL  91
SEQ12      93  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL 101
SEQ14      86  LFQCFNCSLCLNGTVMHLSCEKQNTVCTCHAOFFLRENECVSCSNCKKSL  94
                *****

```

```

SEQ02     150  ECTKLCLPQIEN 161
SEQ04     107  ECTKLCLPQIEN 106
SEQ06     110  ECTKLCLPQIEN 109
SEQ08     107  ECTKLCLPQIEN 106
SEQ10      92  ECTKLCLPQIEN  91
SEQ12     102  ECTKLCLPQIEN 101
SEQ14      95  ECTKLCLPQIEN  94

```



**AMENDMENTS TO THE SPECIFICATION****Marked Up Version of Specification under 37 C.F.R. 1.121(b)(1)(iii)**

Please amend the specification at page 6, line 8 to page 7, line 5 to read as follows:

The truncated sTNFRs of the present invention include polypeptides comprising amino acid residues 1-110, 1-109, 1-108, 1-107, 1-106, 1-105, 1-104, 1-103, 2-110, 2-109, 2-108, 2-107, 2-106, 2-105, 2-104, 2-103, 3-110, 3-109, 3-108, 3-107, 3-106, 3-105, 3-104, 3-103, 4-110, 4-109, 4-108, 4-107, 4-106, 4-105, 4-104, 4-103, 5-110, 5-109, 5-108, 5-107, 5-106, 5-105, 5-104, 5-103, 6-110, 6-109, 6-108, 6-107, 6-106, 6-105, 6-104, 6-103, 7-110, 7-109, 7-108, 7-107, 7-106, 7-105, 7-104, 7-103, 8-110, 8-109, 8-108, 8-107, 8-106, 8-105, 8-104, 8-103, 9-110, 9-109, 9-108, 9-107, 9-106, 9-105, 9-104, 9-103, 10-110, 10-109, 10-108, 10-107, 10-106, 10-105, 10-104, 10-103, 11-110, 11-109, 11-108, 11-107, 11-106, 11-105, 11-104, 11-103, 12-110, 12-109, 12-108, 12-107, 12-106, 12-105, 12-104, 12-103, 13-110, 13-109, 13-108, 13-107, 13-106, 13-105, 13-104, 13-103, 14-110, 14-109, 14-108, 14-107, 14-106, 14-105, 14-104, 14-103, 15-110, 15-109, 15-108, 15-107, 15-106, 15-105, 15-104, 15-103, 16-110, 16-109, 16-108, 16-107, 16-106, 16-105, 16-104, 16-103, 17-110, 17-109, 17-108, 17-107, 17-106, 17-105, 17-104, 17-103, 18-110, 18-109, 18-108, 18-107, 18-106, 18-105, ~~or~~ 18-104, 18-103, 19-110, 19-109, 19-108, 19-107, 19-106, 19-105, 19-104, or 19-103 of SEQ ID NO: 2; or variants thereof; provided however, that when the truncated sTNFR polypeptide comprises amino acid residues 3-110, 4-110, 5-110, 6-110, 7-110, 8-110, 9-110, 10-110, 11-110, 12-110, 13-110, 14-110, 15-110, 16-110, 17-110, ~~or~~ 18-110, or 19-110 of SEQ ID NO: 2, the polypeptide does not further comprise amino acid residues 111-161 of SEQ ID NO: 2, or a portion thereof; and optionally further comprising an amino-terminal methionine.

Please amend the specification at page 7, line 13 to page 8, line 24 to read as follows:

The truncated sTNFRs of the present invention also include polypeptides comprising amino acid residues 1-122, 1-121, 1-120, 1-119, 1-118, 1-117, 1-116, 1-115, 2-122, 2-121, 2-120, 2-119, 2-118, 2-117, 2-116, 2-115, 3-122, 3-121, 3-120, 3-119, 3-118, 3-117, 3-116, 3-115, 4-122, 4-121, 4-120, 4-119, 4-118, 4-117, 4-116, 4-115, 5-122, 5-121, 5-120, 5-119, 5-118, 5-



117, 5-116, 5-116, 6-122, 6-121, 6-120, 6-119, 6-118, 6-117, 6-116, 6-115, 7-122, 7-121, 7-120, 7-119, 7-118, 7-117, 7-116, 7-115, 8-122, 8-121, 8-120, 8-119, 8-118, 8-117, 8-116, 8-115, 9-122, 9-121, 9-120, ~~9-119~~, 9-118, 9-117, 9-116, 9-115, 10-122, 10-121, 10-120, 10-119, 10-118, 10-117, 10-116, 10-115, 11-122, 11-121, 11-120, 11-119, 11-118, 11-117, 11-116, 11-115, 12-122, 12-121, 12-120, 12-119, 12-118, 12-117, 12-116, 12-115, 13-122, 13-121, 13-120, 13-119, 13-118, 13-117, 13-116, 13-115, 14-122, 14-121, 14-120, 14-119, 14-118, 14-117, 14-116, 14-115, 15-122, 15-121, 15-120, 15-119, 15-118, 15-117, 15-116, 15-115, 16-122, 16-121, 16-120, 16-119, 16-118, 16-117, 16-116, 16-115, 17-122, 17-121, 17-120, 17-119, 17-118, 17-117, 17-116, 17-115, 18-122, 18-121, 18-120, 18-119, 18-118, 18-117, 18-116, 18-115, 19-122, 19-121, 19-120, 19-119, 19-118, 19-117, 19-116, 19-115, 20-122, 20-121, 20-120, 20-119, 20-118, 20-117, 20-116, 20-115, 21-122, 21-121, 21-120, 21-119, 21-118, 21-117, 21-116, 21-115, 22-122, 22-121, 22-120, 22-119, 22-118, 22-117, 22-116, 22-115, 23-122, 23-121, 23-120, 23-119, 23-118, 23-117, 23-116, 23-115, 24-122, 24-121, 24-120, 24-119, 24-118, 24-117, 24-116, 24-115, 25-122, 25-121, 25-120, 25-119, 25-118, 25-117, 25-116, 25-115, 26-122, 26-121, 26-120, 26-119, 26-118, 26-117, 26-116, 26-115, 27-122, 27-121, 27-120, 27-119, 27-118, 27-117, 27-116, 27-115, 28-122, 28-121, 28-120, 28-119, 28-118, 28-117, 28-116, 28-115, 29-122, 29-121, 29-120, 29-119, 29-118, 29-117, 29-116, 29-115, 30-122, 30-121, 30-120, 30-119, 30-118, 30-117, 30-116, 30-115, 31-122, 31-121, 31-120, 31-119, 31-118, 31-117, ~~or 31-116~~, 31-115, 32-122, 32-121, 32-120, 32-119, 32-118, 32-117, 32-116, or 32-115 of SEQ ID NO: 16;

or variants and derivatives thereof; provided however, that when the truncated sTNFR polypeptide comprises the amino acid residues 15-122, 16-122, 17-122, 18-122, 19-122, 20-122, 21-122, 22-122, 23-122, 24-122, 25-122, 26-122, 27-122, 28-122, 29-122, 30-122, ~~or 31-122~~, or 32-122 of SEQ ID NO: 16, the polypeptide does not further comprise amino acid residues 123-179 of SEQ ID NO: 16, or a portion thereof; and optionally further comprising an amino-terminal methionine.

Please amend the specification at page 14, line 1 to page 16, line 12 to read as follows:

As used herein, the term "truncated sTNFR(s)" includes one or more biologically active synthetic or recombinant molecules comprising amino acid residues 1-110, 1-109, 1-108, 1-107, 1-106, 1-105, 1-104, 1-103, 2-110, 2-109, 2-108, 2-107, 2-106, 2-105, 2-104, 2-103, 3-110, 3-



109, 3-108, 3-107, 3-106, 3-105, 3-104, 3-103, 4-110, 4-109, 4-108, 4-107, 4-106, 4-105, 4-104, 4-103, 5-110, 5-109, 5-108, 5-107, 5-106, 5-105, 5-104, 5-103, 6-110, 6-109, 6-108, 6-107, 6-106, 6-105, 6-104, 6-103, 7-110, 7-109, 7-108, 7-107, 7-106, 7-105, 7-104, 7-103, 8-110, 8-109, 8-108, 8-107, 8-106, 8-105, 8-104, 8-103, 9-110, 9-109, 9-108, 9-107, 9-106, 9-105, 9-104, 9-103, 10-110, 10-109, 10-108, 10-107, 10-106, 10-105, 10-104, 10-103, 11-110, 11-109, 11-108, 11-107, 11-106, 11-105, 11-104, 11-103, 12-110, 12-109, 12-108, 12-107, 12-106, 12-105, 12-104, 12-103, 13-110, 13-109, 13-108, 13-107, 13-106, 13-105, 13-104, 13-103, 14-110, 14-109, 14-108, 14-107, 14-106, 14-105, 14-104, 14-103, 15-110, 15-109, 15-108, 15-107, 15-106, 15-105, 15-104, 15-103, 16-110, 16-109, 16-108, 16-107, 16-106, 16-105, 16-104, 16-103, 17-110, 17-109, 17-108, 17-107, 17-106, 17-105, 17-104, 17-103, 18-110, 18-109, 18-108, 18-107, 18-106, 18-105, ~~or 18-104~~, 18-103, 19-110, 19-109, 19-108, 19-107, 19-106, 19-105, 19-104, or 19-103 of SEQ ID NO: 2; and variants (including insertion, substitution and deletion variants) thereof (as described below); provided however, that when the truncated sTNFR polypeptide comprises amino acid residues 3-110, 4-110, 5-110, 6-110, 7-110, 8-110, 9-110, 10-110, 11-110, 12-110, 13-110, 14-110, 15-110, 16-110, 17-110, ~~or 18-110~~, or 19-110 of SEQ ID NO: 2, the polypeptide does not further comprise amino acid residues 111-161 of SEQ ID NO: 2, or a portion thereof; and optionally further comprising an amino-terminal methionine. The term "truncated sTNFR(s)" also includes one or more biologically active synthetic or recombinant molecules comprising amino acid residues 1-122, 1-121, 1-120, 1-119, 1-118, 1-117, 1-116, 1-115, 2-122, 2-121, 2-120, 2-119, 2-118, 2-117, 2-116, 2-115, 3-122, 3-121, 3-120, 3-119, 3-118, 3-117, 3-116, 3-115, 4-122, 4-121, 4-120, 4-119, 4-118, 4-117, 4-116, 4-115, 5-122, 5-121, 5-120, 5-119, 5-118, 5-117, 5-116, 5-115, 6-122, 6-121, 6-120, 6-119, 6-118, 6-117, 6-116, 6-115, 7-122, 7-121, 7-120, 7-119, 7-118, 7-117, 7-116, 7-115, 8-122, 8-121, 8-120, 8-119, 8-118, 8-117, 8-116, 8-115, 9-122, 9-121, 9-120, 9-119, 9-118, 9-117, 9-116, 9-115, 10-122, 10-121, 10-120, 10-119, 10-118, 10-117, 10-116, 10-115, 11-122, 11-121, 11-120, 11-119, 11-118, 11-117, 11-116, 11-115, 12-122, 12-121, 12-120, 12-119, 12-118, 12-117, 12-116, 12-115, 13-122, 13-121, 13-120, 13-119, 13-118, 13-117, 13-116, 13-115, 14-122, 14-121, 14-120, 14-119, 14-118, 14-117, 14-116, 14-115, 15-122, 15-121, 15-120, 15-119, 15-118, 15-117, 15-116, 15-115, 16-122, 16-121, 16-120, 16-119, 16-118, 16-117, 16-116, 16-115, 17-122, 17-121, 17-120, 17-119, 17-118, 17-117, 17-116, 17-115, 18-122, 18-121, 18-120, 18-119, 18-118, 18-117, 18-116, 18-115, 19-122, 19-121, 19-120, 19-119, 19-118, 19-117, 19-116, 19-115, 20-122, 20-121, 20-120,



20-119, 20-118, 20-117, 20-116, 20-115, 21-122, 21-121, 21-120, 21-119, 21-118, 21-117, 21-116, 21-115, 22-122, 22-121, 22-120, 22-119, 22-118, 22-117, 22-116, 22-115, 23-122, 23-121, 23-120, 23-119, 23-118, 23-117, 23-116, 23-115, 24-122, 24-121, 24-120, 24-119, 24-118, 24-117, 24-116, 24-115, 25-122, 25-121, 25-120, 25-119, 25-118, 25-117, 25-116, 25-115, 26-122, 26-121, 26-120, 26-119, 26-118, 26-117, 26-116, 26-115, 27-122, 27-121, 27-120, 27-119, 27-118, 27-117, 27-116, 27-115, 28-122, 28-121, 28-120, 28-119, 28-118, 28-117, 28-116, 28-115, 29-122, 29-121, 29-120, 29-119, 29-118, 29-117, 29-116, 29-115, 30-122, 30-121, 30-120, 30-119, 30-118, 30-117, 30-116, 30-115, 31-122, 31-121, 31-120, 31-119, 31-118, 31-117, ~~or~~ 31-116, 31-115, 32-122, 32-121, 32-120, 32-119, 32-118, 32-117, 32-116, or 32-115 of SEQ ID NO: 16; and variants (including insertion, substitution and deletion variants) thereof (as described below); provided however, that when the truncated sTNFR polypeptide comprises the amino acid residues 15-122, 16-122, 17-122, 18-122, 19-122, 20-122, 21-122, 22-122, 23-122, 24-122, 25-122, 26-122, 27-122, 28-122, 29-122, 30-122, ~~or~~ 31-122, or 32-122 of SEQ ID NO: 16, the polypeptide does not further comprise amino acid residues 123-179 of SEQ ID NO: 16, or a portion thereof; and optionally further comprising an amino-terminal methionine.

Please amend the specification at page 17, line 18 to page 19, line 24 to read as follows:

In one basic embodiment, truncated sTNFRs of the present invention may be one or more polypeptides comprising amino acid residues 1-110, 1-109, 1-108, 1-107, 1-106, 1-105, 1-104, 1-103, 2-110, 2-109, 2-108, 2-107, 2-106, 2-105, 2-104, 2-103, 3-110, 3-109, 3-108, 3-107, 3-106, 3-105, 3-104, 3-103, 4-110, 4-109, 4-108, 4-107, 4-106, 4-105, 4-104, 4-103, 5-110, 5-109, 5-108, 5-107, 5-106, 5-105, 5-104, 5-103, 6-110, 6-109, 6-108, 6-107, 6-106, 6-105, 6-104, 6-103, 7-110, 7-109, 7-108, 7-107, 7-106, 7-105, 7-104, 7-103, 8-110, 8-109, 8-108, 8-107, 8-106, 8-105, 8-104, 8-103, 9-110, 9-109, 9-108, 9-107, 9-106, 9-105, 9-104, 9-103, 10-110, 10-109, 10-108, 10-107, 10-106, 10-105, 10-104, 10-103, 11-110, 11-109, 11-108, 11-107, 11-106, 11-105, 11-104, 11-103, 12-110, 12-109, 12-108, 12-107, 12-106, 12-105, 12-104, 12-103, 13-110, 13-109, 13-108, 13-107, 13-106, 13-105, 13-104, 13-103, 14-110, 14-109, 14-108, 14-107, 14-106, 14-105, 14-104, 14-103, 15-110, 15-109, 15-108, 15-107, 15-106, 15-105, 15-104, 15-103, 16-110, 16-109, 16-108, 16-107, 16-106, 16-105, 16-104, 16-103, 17-110, 17-109, 17-108, 17-107, 17-106, 17-105, 17-104, 17-103, 18-110, 18-109, 18-108, 18-107, 18-106, 18-105, ~~or~~ 18-104,



18-103, 19-110, 19-109, 19-108, 19-107, 19-106, 19-105, 19-104, or 19-103 of SEQ ID NO: 2; or variants thereof, provided however, that when the truncated sTNFR polypeptide comprises amino acid residues 3-110, 4-110, 5-110, 6-110, 7-110, 8-110, 9-110, 10-110, 11-110, 12-110, 13-110, 14-110, 15-110, 16-110, 17-110, ~~or 18-110~~, or 19-110 of SEQ ID NO: 2, the polypeptide does not further comprise amino acid residues 111-161 of SEQ ID NO: 2, or a portion thereof.

In another basic embodiment, truncated sTNFRs of the present invention may be one or more polypeptides comprising amino acid residues 1-122, 1-121, 1-120, 1-119, 1-118, 1-117, 1-116, 1-115, 2-122, 2-121, 2-120, 2-119, 2-118, 2-117, 2-116, 2-115, 3-122, 3-121, 3-120, 3-119, 3-118, 3-117, 3-116, 3-115, 4-122, 4-121, 4-120, 4-119, 4-118, 4-117, 4-116, 4-115, 5-122, 5-121, 5-120, 5-119, 5-118, 5-117, 5-116, 5-115, 6-122, 6-121, 6-120, 6-119, 6-118, 6-117, 6-116, 6-115, 7-122, 7-121, 7-120, 7-119, 7-118, 7-117, 7-116, 7-115, 8-122, 8-121, 8-120, 8-119, 8-118, 8-117, 8-116, 8-115, 9-122, 9-121, 9-120, 9-119, 9-118, 9-117, 9-116, 9-115, 10-122, 10-121, 10-120, 10-119, 10-118, 10-117, 10-116, 10-115, 11-122, 11-121, 11-120, 11-119, 11-118, 11-117, 11-116, 11-115, 12-122, 12-121, 12-120, 12-119, 12-118, 12-117, 12-116, 12-115, 13-122, 13-121, 13-120, 13-119, 13-118, 13-117, 13-116, 13-115, 14-122, 14-121, 14-120, 14-119, 14-118, 14-117, 14-116, 14-115, 15-122, 15-121, 15-120, 15-119, 15-118, 15-117, 15-116, 15-115, 16-122, 16-121, 16-120, 16-119, 16-118, 16-117, 16-116, 16-115, 17-122, 17-121, 17-120, 17-119, 17-118, 17-117, 17-116, 17-115, 18-122, 18-121, 18-120, 18-119, 18-118, 18-117, 18-116, 18-115, 19-122, 19-121, 19-120, 19-119, 19-118, 19-117, 19-116, 19-115, 20-122, 20-121, 20-120, 20-119, 20-118, 20-117, 20-116, 20-115, 21-122, 21-121, 21-120, 21-119, 21-118, 21-117, 21-116, 21-115, 22-122, 22-121, 22-120, 22-119, 22-118, 22-117, 22-116, 22-115, 23-122, 23-121, 23-120, 23-119, 23-118, 23-117, 23-116, 23-115, 24-122, 24-121, 24-120, 24-119, 24-118, 24-117, 24-116, 24-115, 25-122, 25-121, 25-120, 25-119, 25-118, 25-117, 25-116, 25-115, 26-122, 26-121, 26-120, 26-119, 26-118, 26-117, 26-116, 26-115, 27-122, 27-121, 27-120, 27-119, 27-118, 27-117, 27-116, 27-115, 28-122, 28-121, 28-120, 28-119, 28-118, 28-117, 28-116, 28-115, 29-122, 29-121, 29-120, 29-119, 29-118, 29-117, 29-116, 29-115, 30-122, 30-121, 30-120, 30-119, 30-118, 30-117, 30-116, 30-115, 31-122, 31-121, 31-120, 31-119, 31-118, 31-117, ~~or 31-116~~, 31-115, 32-122, 32-121, 32-120, 32-119, 32-118, 32-117, 32-116, or 32-115 of SEQ ID NO: 16;

or variants thereof, provided however, that when the truncated sTNFR polypeptide comprises the amino acid residues 15-122, 16-122, 17-122, 18-122, 19-122, 20-122, 21-122, 22-122, 23-122,



24-122, 25-122, 26-122, 27-122, 28-122, 29-122, 30-122, ~~or 31-122, or 32-122~~ of SEQ ID NO: 16, the polypeptide does not further comprise amino acid residues 123-179 of SEQ ID NO: 16, or a portion thereof.



**AMENDMENTS TO THE CLAIMS****Marked Up Versions of Amended Claims under 37 C.F.R. 1.121(c)(1)(ii)**

1. (Twice Amended) A truncated sTNFR polypeptide comprising amino acid residues 1-110, 1-109, 1-108, 1-107, 1-106, 1-105, 1-104, 1-103, 2-110, 2-109, 2-108, 2-107, 2-106, 2-105, 2-104, 2-103, 3-110, 3-109, 3-108, 3-107, 3-106, 3-105, 3-104, 3-103, 4-110, 4-109, 4-108, 4-107, 4-106, 4-105, 4-104, 4-103, 5-110, 5-109, 5-108, 5-107, 5-106, 5-105, 5-104, 5-103, 6-110, 6-109, 6-108, 6-107, 6-106, 6-105, 6-104, 6-103, 7-110, 7-109, 7-108, 7-107, 7-106, 7-105, 7-104, 7-103, 8-110, 8-109, 8-108, 8-107, 8-106, 8-105, 8-104, 8-103, 9-110, 9-109, 9-108, 9-107, 9-106, 9-105, 9-104, 9-103, 10-110, 10-109, 10-108, 10-107, 10-106, 10-105, 10-104, 10-103, 11-110, 11-109, 11-108, 11-107, 11-106, 11-105, 11-104, 11-103, 12-110, 12-109, 12-108, 12-107, 12-106, 12-105, 12-104, 12-103, 13-110, 13-109, 13-108, 13-107, 13-106, 13-105, 13-104, 13-103, 14-110, 14-109, 14-108, 14-107, 14-106, 14-105, 14-104, 14-103, 15-110, 15-109, 15-108, 15-107, 15-106, 15-105, 15-104, 15-103, 16-110, 16-109, 16-108, 16-107, 16-106, 16-105, 16-104, 16-103, 17-110, 17-109, 17-108, 17-107, 17-106, 17-105, 17-104, 17-103, 18-110, 18-109, 18-108, 18-107, 18-106, 18-105, ~~or 18-104~~, 18-103, 19-110, 19-109, 19-108, 19-107, 19-106, 19-105, 19-104, or 19-103 of SEQ ID NO: 2;  
 or variants and derivatives thereof; provided however, that when the truncated sTNFR polypeptide comprises amino acid residues 3-110, 4-110, 5-110, 6-110, 7-110, 8-110, 9-110, 10-110, 11-110, 12-110, 13-110, 14-110, 15-110, 16-110, 17-110, ~~or 18-110~~, or 19-110 of SEQ ID NO: 2, the polypeptide does not further comprise amino acid residues 111-161 of SEQ ID NO: 2, or a portion thereof;  
 and optionally further comprising an amino-terminal methionine.

3. (Twice Amended) A truncated sTNFR polypeptide comprising amino acid residues 1-122, 1-121, 1-120, 1-119, 1-118, 1-117, 1-116, 1-115, 2-122, 2-121, 2-120, 2-119, 2-118, 2-117, 2-116, 2-115, 3-122, 3-121, 3-120, 3-119, 3-118, 3-117, 3-116, 3-115, 4-122, 4-121, 4-120, 4-119, 4-118, 4-117, 4-116, 4-115, 5-122, 5-121, 5-120, 5-119, 5-118, 5-117, 5-116, 5-115, 6-122, 6-121, 6-120, 6-119, 6-118, 6-117, 6-116, 6-115, 7-122, 7-121, 7-120, 7-119, 7-118, 7-117, 7-116, 7-115, 8-122, 8-121, 8-120, 8-119, 8-118, 8-117, 8-116, 8-115, 9-122, 9-121, 9-120, 9-119, 9-118, 9-117, 9-116, 9-115, 10-122, 10-121, 10-120, 10-119, 10-118, 10-117, 10-116, 10-115,



11-122, 11-121, 11-120, 11-119, 11-118, 11-117, 11-116, 11-115, 12-122, 12-121, 12-120, 12-119, 12-118, 12-117, 12-116, 12-115, 13-122, 13-121, 13-120, 13-119, 13-118, 13-117, 13-116, 13-115, 14-122, 14-121, 14-120, 14-119, 14-118, 14-117, 14-116, 14-115, 15-122, 15-121, 15-120, 15-119, 15-118, 15-117, 15-116, 15-115, 16-122, 16-121, 16-120, 16-119, 16-118, 16-117, 16-116, 16-115, 17-122, 17-121, 17-120, 17-119, 17-118, 17-117, 17-116, 17-115, 18-122, 18-121, 18-120, 18-119, 18-118, 18-117, 18-116, 18-115, 19-122, 19-121, 19-120, 19-119, 19-118, 19-117, 19-116, 19-115, 20-122, 20-121, 20-120, 20-119, 20-118, 20-117, 20-116, 20-115, 21-122, 21-121, 21-120, 21-119, 21-118, 21-117, 21-116, 21-115, 22-122, 22-121, 22-120, 22-119, 22-118, 22-117, 22-116, 22-115, 23-122, 23-121, 23-120, 23-119, 23-118, 23-117, 23-116, 23-115, 24-122, 24-121, 24-120, 24-119, 24-118, 24-117, 24-116, 24-115, 25-122, 25-121, 25-120, 25-119, 25-118, 25-117, 25-116, 25-115, 26-122, 26-121, 26-120, 26-119, 26-118, 26-117, 26-116, 26-115, 27-122, 27-121, 27-120, 27-119, 27-118, 27-117, 27-116, 27-115, 28-122, 28-121, 28-120, 28-119, 28-118, 28-117, 28-116, 28-115, 29-122, 29-121, 29-120, 29-119, 29-118, 29-117, 29-116, 29-115, 30-122, 30-121, 30-120, 30-119, 30-118, 30-117, 30-116, 30-115, 31-122, 31-121, 31-120, 31-119, 31-118, 31-117, ~~or~~ 31-116, 31-115, 32-122, 32-121, 32-120, 32-119, 32-118, 32-117, 32-116, or 32-115 of SEQ ID NO: 16;

or variants and derivatives thereof; provided however, that when the truncated sTNFR polypeptide comprises the amino acid residues 15-122, 16-122, 17-122, 18-122, 19-122, 20-122, 21-122, 22-122, 23-122, 24-122, 25-122, 26-122, 27-122, 28-122, 29-122, 30-122, ~~or~~ 31-122, or 32-122 of SEQ ID NO: 16, the polypeptide does not further comprise amino acid residues 123-179 of SEQ ID NO: 16, or a portion thereof;

and optionally further comprising an amino-terminal methionine.





McDonnell Boehnen Hulbert & Berghoff  
Law Offices

## Fax transmittal

To Eileen B. O'Hara  
Company U.S. Patent & Trademark Office  
Fax 703-308-4242  
Phone 703-308-3312  
Pages, 22  
with cover  
Re Application Serial No. 09/882,735

Date November 12, 2002  
From Donald L. Zuhn Jr.  
Direct 312-913-2132  
Email zuhn@mbhb.com  
C/M 349-162

200 South Wacker Drive 312-913-6901 phone  
Chicago, Illinois 60606-5709 312-913-0002 fax  
www.mbh.com

Please notify receptionist if all  
pages are not received.  
If you received this fax in error,  
please notify us immediately by  
phone (collect) to arrange for  
return of the document.

This transmittal is strictly for  
confidentiality only to the person listed  
above. It may contain confidential  
or privileged information, the  
disclosure of which is prohibited.